Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Royalty Pharma (RPRX) just unveiled an update.
Servier’s new drug Voranigo has gained FDA approval, promising treatment for patients with a specific type of brain cancer. Under a lucrative deal, Royalty Pharma will pay Agios $905 million for a slice of Voranigo’s future sales, betting on the drug’s success with projected annual sales exceeding $1 billion and generating substantial royalties possibly until 2038. This deal underscores the high stakes and potential rewards in pharmaceutical investments.
For an in-depth examination of RPRX stock, go to TipRanks’ Stock Analysis page.